Crescent BiopharmaCBIO +0.22%10 Market Cap is $496.35 Mil as of Jun. 30, 2026. GuruFocus rates CBIO with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,428 Biotechnology companies, Crescent Biopharma ranks better than 71.01% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Crescent Biopharma's share price for the quarter that ended in Mar. 2026 was $18.37. Crescent Biopharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 27.58 Mil. Therefore, Crescent Biopharma's market cap for the quarter that ended in Mar. 2026 was $506.55 Mil.
Crescent Biopharma's quarterly market cap
increased
from Sep. 2025 ($199.55 Mil) to Dec. 2025 ($361.10 Mil) and
increased
from Dec. 2025 ($361.10 Mil) to Mar. 2026 ($506.55 Mil).
Crescent Biopharma's annual market cap
stayed the same
from . 20 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then
increased
from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($361.10 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Crescent Biopharma's Enterprise Value for Today is $312.73 Mil.
Crescent Biopharma (NAS:CBIO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Crescent Biopharma Market Cap Related Terms
Crescent Biopharma Market Cap Historical Data
* Premium members only.
The historical data trend for Crescent Biopharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Crescent Biopharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescent Biopharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crescent Biopharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Crescent Biopharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Crescent Biopharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescent Biopharma (CBIO) has a Market Cap of $496.35 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Crescent Biopharma and its competitors. According to the industry distribution chart, Crescent Biopharma ranks #414 out of 1428 companies in the Biotechnology industry, placing it in the top 29%.
Is Crescent Biopharma's Market Cap too high?
Crescent Biopharma's current Market Cap is $496.35 Mil. The Biotechnology industry median Market Cap is 119.44. Crescent Biopharma's value of $496.35 Mil is 315.6% above this industry median. Based on the distribution chart, Crescent Biopharma ranks #414 out of 1428 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Market Cap compare to KYTX and ZURA?
According to the Biotechnology industry distribution chart, Crescent Biopharma ranks #414 out of 1428 companies for Market Cap. This puts Crescent Biopharma in the upper half of its industry. The industry median Market Cap is 119.44. Crescent Biopharma's value of $496.35 Mil is 315.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.44, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crescent Biopharma's current Market Cap of $496.35 Mil is 315.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Crescent Biopharma and its competitors. For the Biotechnology industry, the median Market Cap is 119.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crescent Biopharma's current Market Cap is $496.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (CBIO) has a current Market Cap of $496.35 Mil. The current Market Cap is $496.35 Mil and 315.6% above the Biotechnology industry median of 119.44. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Crescent Biopharma (CBIO), the current Market Cap is $496.35 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score
Get the complete analysis for CBIO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBIO has been successfully added to your 